Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging

Core Viewpoint - Longeveron Inc. has received a Canadian patent for its proprietary mesenchymal stem cell therapy, laromestrocel (LOMECEL-B), aimed at treating aging-related frailty and non-ischemic dilated cardiomyopathy, which positions the company favorably in the biotechnology sector focused on regenerative medicine [1][2][8] Company Overview - Longeveron Inc. is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs, with its lead product being laromestrocel, an allogeneic mesenchymal stem cell therapy derived from the bone marrow of young, healthy adult donors [7] - The company is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer's disease, and pediatric dilated cardiomyopathy (DCM) [7] Patent Details - The Canadian Patent No. 3043594 grants Longeveron rights to administer laromestrocel for treating aging-related frailty and non-ischemic dilated cardiomyopathy until 2037 [2][8] - The patent covers methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells to patients with aging-related frailty and NIDCM [8] Clinical Research - Longeveron has conducted Phase 1 and 2 studies demonstrating improvements in physical functioning and the six-minute walk test for aging-related frailty using laromestrocel [4][8] - Non-ischemic dilated cardiomyopathy is a progressive disorder with no current cure, and laromestrocel has shown potential in altering immunologic markers associated with chronic inflammation [5][8] Mechanism of Action - Laromestrocel is believed to have multiple mechanisms of action, including anti-inflammatory and pro-vascular regenerative responses, which may have broad applications for various rare and aging-related diseases [6][7]